Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02746991 |
Recruitment Status :
Completed
First Posted : April 21, 2016
Results First Posted : July 7, 2020
Last Update Posted : July 21, 2020
|
Sponsor:
EyePoint Pharmaceuticals, Inc.
Information provided by (Responsible Party):
EyePoint Pharmaceuticals, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date ICMJE | April 19, 2016 | |||
First Posted Date ICMJE | April 21, 2016 | |||
Results First Submitted Date ICMJE | June 17, 2020 | |||
Results First Posted Date ICMJE | July 7, 2020 | |||
Last Update Posted Date | July 21, 2020 | |||
Actual Study Start Date ICMJE | June 2, 2015 | |||
Actual Primary Completion Date | October 4, 2019 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures ICMJE |
Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months [ Time Frame: 6 Months ] Proportion of Subjects with Recurrence of Uveitis in the Study Eye within 6 Months Including Reason for Imputed Recurrence (ITT Population)
|
|||
Original Primary Outcome Measures ICMJE |
Recurrence of uveitis in study eye [ Time Frame: Six Months ] | |||
Change History | ||||
Current Secondary Outcome Measures ICMJE |
Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months [ Time Frame: 36 Months ] Proportion of Subjects with Recurrence of Uveitis in the Study Eye at 36 Months Including Reason for Imputed Recurrence (ITT Population)
|
|||
Original Secondary Outcome Measures ICMJE |
Recurrence of uveitis in study eye [ Time Frame: Three Years ] | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures |
|
|||
Descriptive Information | ||||
Brief Title ICMJE | Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis | |||
Official Title ICMJE | A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye | |||
Brief Summary | Phase 3, multi-center, randomized, masked, controlled study to evaluate the safety and efficacy of an injectable fluocinolone acetonide intravitreal (FAI) insert for the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye. Patients will be randomized to receive either a sham injection or the FAI insert and will be observed for three years following treatment. | |||
Detailed Description | This is a phase 3, multi-center, randomized, masked, controlled study to evaluate the safety and efficacy of an injectable fluocinolone acetonide intravitreal (FAI) insert for the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye. Patients will be randomized to receive either a sham injection or the FAI insert and will be observed for three years following treatment. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Outcomes Assessor) Primary Purpose: Treatment |
|||
Condition ICMJE |
|
|||
Intervention ICMJE |
|
|||
Study Arms ICMJE |
|
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE |
153 | |||
Original Estimated Enrollment ICMJE |
150 | |||
Actual Study Completion Date ICMJE | October 4, 2019 | |||
Actual Primary Completion Date | October 4, 2019 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
OR the study eye has experienced recurrence: • at least 2 separate recurrences of uveitis requiring systemic, intra- or peri-ocular injection of corticosteroid Exclusion Criteria:
|
|||
Sex/Gender ICMJE |
|
|||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | India | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT02746991 | |||
Other Study ID Numbers ICMJE | PSV-FAI-005 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Current Responsible Party | EyePoint Pharmaceuticals, Inc. | |||
Original Responsible Party | Same as current | |||
Current Study Sponsor ICMJE | EyePoint Pharmaceuticals, Inc. | |||
Original Study Sponsor ICMJE | Same as current | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
|
|||
PRS Account | EyePoint Pharmaceuticals, Inc. | |||
Verification Date | July 2020 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |